Tag: CBD
-
![What are psychedelics companies like Psyense (PSYG.C), Havn (HAVN.C), Canbud (CBDX.C) and Field Trip (FTRP.C) all doing in Jamaica?]()
What are psychedelics companies like Psyense (PSYG.C), Havn (HAVN.C), Canbud (CBDX.C) and Field Trip (FTRP.C) all doing in Jamaica?
Shroom tea Jamaica is one of the few countries in the world where the sale and consumption of psilocybin is legal, and through my DD, it’s incredibly easy to attain. The country isn’t new to foreigners tripping there, tourists have been visiting the island for decades for its famous magic mushroom teas. For people who…
-
![As Australia opens to cannabis, Canntab’s (PILL.C) tech might just claim the box seat]()
As Australia opens to cannabis, Canntab’s (PILL.C) tech might just claim the box seat
News this week that Canntab Therapeutics (PILL.C) received an Australian patent for their hard-pressed cannabis pill tech, to match those received earlier in North America, didn’t launch the stock into space. That’s understandable, to be honest, as North American investors have taken an eye off the island continent and its slow roll to weed legalization…
-
![Heritage Cannabis (CANN.C) Exceeds $1M in Weekly Revenue]()
Heritage Cannabis (CANN.C) Exceeds $1M in Weekly Revenue
Heritage Cannabis (CANN.C) achieved a weekly revenue exceeding $1 million during the second week of March, 2021. “This achievement is an exciting milestone for Heritage as we continue to develop and innovate new products within our already popular brands…while there is still much more work to be done to make this a consistent outcome, we…
-
Pure Extracts (PULL.C) looks to level up with dealers license application
At a time when many cannabis companies are enjoying bursts of investor interest, management at BC-based extractor Pure Extracts (PULL.C) must be getting frustrated as they roll out new contracts, new manufacturing lines, and advance in their pursuit of licensing that would allow them to break out into psychedelics. In essence, they’re hitting all the…
-
Pure Extracts (PULL.C) submits 20 SKUs to Health Canada, based on its proprietary CO2 extraction technology
PULL submitted over 20 Stock Keeping Units (SKU) product identifiers for approval including THC vapes, CBD vapes, 1:1 blended vapes, and 3 different flavours/formulations of gummies.
-
That was quick! Xphyto (XPHY.C) orders 9,600 Covid-19 PCR tests – stock up 67% year-to-date
“PCR tests are used to directly detect the presence of an antigen, rather than the presence of the body’s immune response, or antibodies,” states Medical Device Network, “By detecting viral RNA, which will be present in the body before symptoms of the disease are present,” the tests give a powerful early warning system.
-
![Xphyto (XPHY.C) assembles biotech/biz dream-team to launch 25-minute Covid-19 test]()
Xphyto (XPHY.C) assembles biotech/biz dream-team to launch 25-minute Covid-19 test
The PCR test system demonstrated clinical accuracy in detecting SARS-CoV-2 RNA within 25 minutes, making it an ideal screening tool for international airports.
-
![Pure Extracts (PULL.C) cuts a licensing deal with Taste-T, the maker of Fireball Cannabis Gummies]()
Pure Extracts (PULL.C) cuts a licensing deal with Taste-T, the maker of Fireball Cannabis Gummies
Included in the agreement is the delivery to Pure Extracts’ British Columbia facility of one of Taste-T’s custom built gummie-manufacturing machines, certified to Canadian standards.
-
Canntab (PILL.C) yeets another patent for hard-pressed, long release cannabis pills
I’ve made no secret of the fact that the Canadian cannabis market frequently annoys the hell out of me. What I want is for it to be a mature space that more and more adults are making use of, and that is free to innovate, free to be excellent, free to market itself properly, and…
-
![Xphyto’s (XPHY.C) lays out its ambitious Parkinson’s/Epilepsy/Depression/Multiple Sclerosis drug formulation strategy which includes heavy investment in psychedelic medicine]()
Xphyto’s (XPHY.C) lays out its ambitious Parkinson’s/Epilepsy/Depression/Multiple Sclerosis drug formulation strategy which includes heavy investment in psychedelic medicine
Xphyto describes itself as “a bioscience accelerator” “targeting growth through commercialization of its product pipeline”.
